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Available online 27 April 2016Background: Incomplete hippocampal inversion (IHI), also called malrotation, is a frequent atypical anatomical
pattern of the hippocampus. Because of the crucial implication of the hippocampus inMajor Depressive Disorder
(MDD) and the neurodevelopmental hypothesis of MDD, we aimed to assess the prevalence of IHI in patients
with MDD, the link of IHI with hippocampal volume (HV) and the impact of IHI on the predictive value of HV
for response and remission after antidepressant treatment.
Methods: IHI (right and left, partial and total and IHI scores) and HV were assessed in 60 patients with a current
Major Depressive Episode (MDE) in a context of MDD and 60 matched controls. Patients were prospectively
assessed at baseline and after one, three and sixmonths of antidepressant treatment for response and remission.
Results: The prevalence of IHI did not signiﬁcantly differ betweenMDDpatients (right=23.3%; left=38.3%) and
controls (right = 16.7%; left = 33.3%). IHI was not signiﬁcantly associated with MDD clinical characteristics. IHI
alone did not predict response and remission after antidepressant treatment. However, an interaction between
left HV and left IHI predicted six-month response (p = 0.04), HDRS score decrease (p = 0.02) and both three-
month (p = 0.04) and six-month (p = 0.03) remission. A case-control design in 30 matched patients with or
without left IHI conﬁrmed that interaction. In patients without left IHI, left HV at baseline were smaller in six-
month non-remitters as compared to remitters (2.2(±0.43) cm3 vs 2.97(±0.5) cm3 p = 0.02), and in six-
month non-responders as compared to responders (2.18(±0.42) cm3 vs 2.86(±0.54) cm3, p=0.03). In patients
with left IHI, no association was found between left HV at baseline and antidepressant response and remission.
Conclusion: IHI is notmore frequent inMDDpatients than in controls, is not associatedwithHV, but is a confounder
that decreases the predictive value of hippocampal volume to predict response or remission after antidepressant
treatment. IHI should be systematically assessed in future research studies assessing hippocampal volume inMDD.










. This is an open access article under1. Introduction
Incomplete Hippocampal Inversion (IHI), also called hippocampal
malrotation, is an atypical anatomical pattern of the hippocampus
(Bajic et al., 2008; Baulac et al., 1998; Bernasconi et al., 2005; Cury
et al., 2015). Its main features are a round and vertical hippocampal
body in a coronal plane, a medial positioning of the hippocampus and
a deep and vertical collateral sulcus (Bajic et al., 2008; Baulac et al.,
1998; Bernasconi et al., 2005; Cury et al., 2015) (Fig. 1).the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Example of temporal media lobe without and with incomplete hippocampai
inversion in MRI coronal view. Top row shows hippocampl (H) without incomplete
hippocampal inversion (IHI), they have a ﬂat shape and horizontal orientation and
normal sulci shape. Bottom row shows hippocampi (H) with IHI, they have a rounded
shape and a medial positioning; the left one presents a deep and vertical collateral
sulcus (CS).
950 R. Colle et al. / NeuroImage: Clinical 12 (2016) 949–955IHI was initially described in patients with epilepsy, with a prev-
alence of 30% to 50% (Bajic et al., 2009; Bajic et al., 2008; Baulac et al.,
1998; Bernasconi et al., 2005; Lehericy et al., 1995; Raininko and
Bajic, 2010). However, IHI is not speciﬁc to epilepsy and has also
been reported in healthy subjects (Bajic et al., 2008; Bernasconi
et al., 2005; Bronen and Cheung, 1991). A recent study assessed the
prevalence of IHI in the general population in a large sample of
over 2000 subjects (Cury et al., 2015). IHI can be total (all the criteria
for IHI) or partial. It is a frequent phenomenon in healthy subjects
and is more frequent in the left (17.1% for total IHI and 11.9% for par-
tial IHI) than in the right hippocampus (6.5% for total IHI and 9% for
partial IHI)(Cury et al., 2015). Although its frequency is lower than
in patients with epilepsy, IHI is thus a common phenomenon in the
general population and should be taken into account in morphomet-
ric studies. Furthermore, IHI is shown to impact the accuracy of auto-
matic hippocampal segmentation methods and may thus be a
cofounder of volumetric analyses (Kim et al., 2012).
IHI is thought to be of developmental origin, as shown by studies in
neonates (Raininko and Bajic, 2010; Righini et al., 2006). Furthermore,
IHI is associated with different developmental defects, including agene-
sis of the corpus callosum (Atlas et al., 1986), and genetic abnormalities
(Andrade et al., 2013; Atlas et al., 1986; Baker et al., 2011; Boronat et al.,
2015; Campbell et al., 2006; Grosso et al., 2003). Finally, subjects with
IHI display morphological changes in several sulci outside the medial
temporal lobe (Cury et al., 2015). These different elements suggest
that IHI may thus be a sign of atypical brain development.
The hippocampus is a key cerebral structure for the physiopathology
ofMajor DepressiveDisorder (MDD), it is associatedwithmemory func-
tion and a focus of neurogenesis (MacQueen and Frodl, 2011). Several
studies have shown that MDD patients have smaller hippocampal
volumes (HV) than controls (Kempton et al., 2011). Moreover, in
MDD patients, smaller HV predict lower response and remission after
antidepressant treatment, as shown in a recent meta-analysis (Colle
et al., submitted for publication) of 6 studies, of which 2 were positive
and 4 were negative (18–23). However, the effect size is moderate.
Therefore, response and remission after antidepressant treatment are
still difﬁcult to predict in depressed patients (Kupfer et al., 2012). To
take into account hippocampal atypical anatomical pattern in addition
to HV could lead to improve accuracy of prediction of response and re-
mission after antidepressant treatment.
Despite the major implication of the hippocampus in Major Depres-
sive Disorder (MDD), the neurodevelopmental hypothesis of MDD that
suggests that early developmental defect could contribute to the phys-
iopathology of MDD (Ansorge et al., 2007), the impact of IHI on MDD
has never been explored.Thus, we aimed at answering the following ﬁve questions. Is IHI
more frequent in MDD patients than in controls? Is IHI associated
with speciﬁc clinical characteristics of MDD? Is IHI related to hippocam-
pal volume in MDD? Is IHI a predictor of response/remission after anti-
depressant treatment in MDD patients? Does taking into account IHI
improve the predictive value of hippocampal volume in the prediction
of response/remission after antidepressant treatment?
2. Materials and methods
2.1. Design
Hippocampal volume and IHIwere assessed at baseline in a 6-month
prospective real-world setting treatment study of patients with a
current Major Depressive Episode (MDE), clinically assessed at the
beginning of antidepressant treatment, 1, 3 and 6 months later and
in controls in a case control design. This study was registered by
the French National Agency for Medicine and Health Products Safety
(ANSM) and the Commission Nationale de l'Informatique et des
Libertés (CNIL), was approved by the Ethics Committee of Paris-
Boulogne, France, and conformed to international ethical standards.
All patients provided written informed consent for study participation.
2.2. Patients and controls
60 consecutive in- or out-patients, aged 18 to 65 years, with a cur-
rent Major Depressive Episode in a context of MDD, with a minimum
score of 18 at the Hamilton Depression Rating Scale-17, HDRS-17
(Hamilton, 1960) were included. They had had a cerebral MRI in the
Neuroradiology department of Bicêtre Hospital and were assessed for
depression at the start of the index antidepressant treatment (M0),
and one (M1), three (M3) and six (M6) months later.
Patients with psychotic symptoms, bipolar disorders, psychotic dis-
orders, eating disorders, current substance abuse or dependence, preg-
nancy, organic brain syndromes or severe unstable medical conditions
were not included. Patients receiving antipsychotics or mood stabilizers
before inclusion and/or for four months or more during the last year
were also excluded. Antipsychotics, mood stabilizers and stimulants
were not permitted during the study. Benzodiazepines at the minimum
effective dose and for theminimumduration and psychotherapies were
allowed. The index antidepressant treatment had to be a monotherapy.
The decision regarding the drug and its dose were left to the treating
psychiatrist, using “real world” treatment options.
The index antidepressant treatment had to belong to one of the
three following classes: Selective Serotonin Reuptake Inhibitors (SSRI)
(n = 20), Serotonin Norepinephrin Reuptake Inhibitors (SNRI) (n =
34) and Tricyclic antidepressants (TCA) (n = 6).
60 controls who had beneﬁted in clinical practice (mainly head-
ache, migraine and vertigo exploration and search for cancer-
associated brain metastases) from a cerebral MRI, in the Neuroradi-
ology department of Bicêtre Hospital, for whose no neurological ab-
normalities were found on the MRI, and matched for sex, age, MRI
acquisition type and MRI acquisition date with the 60 depressed pa-
tients were also included. Controls with psychiatric disorders, cur-
rent substance abuse or dependence, as well as pregnancy, breast
feeding, organic brain syndroms, dementia, epilepsy, or unstable
medical conditions were not included.
2.3. MRI acquisition
Brain MRI acquisitions were performed on 1.5 (n= 92) or 3-T (n=
28) Philips systems. All subjects were scanned with a routine whole
brain T1-weighted 3D sequence.
These images were acquired with a resolution of either
0.6 × 0.6 × 0.7 (interpolated) or 0.88 × 0.88 × 1.1 in sagittal plane, or
with a resolution of 0.94 × 0.94 × 1.00 in axial plane. MRI acquisition
951R. Colle et al. / NeuroImage: Clinical 12 (2016) 949–955sequences were associated neither with age, gender, IHI prevalence nor
with antidepressant response and remission.
2.4. Assessment of IHI
IHI assessment was performed using the protocol deﬁned by Cury
et al. (Cury et al., 2015) (according to Cury et al., 2015). This protocol
comprises a global criterion named C0 and ﬁve individual criteria
(named C1 to C5). The ﬁve individual criteria assess: the verticality
and roundness of the hippocampal body, the depth and verticality of
the collateral sulcus, the medial positioning of the hippocampus, the
thickness of the subiculum and the depth of the sulci of the fusiform
gyrus. The ﬁve criteria are graded from 0 to 2. C0 evaluates the presence
of IHI globally and is deﬁned as follows: 0 is given if the hippocampus
has a common aspect, 1 is given if the hippocampus does not have a
common aspect but not a total IHI which corresponds to a partial IHI,
a grade of 2 is given if the hippocampus has a total IHI. They were all
assessed in the coronal plane and separately for the left and right hippo-
campi. For more details about these criteria, the reader is referred to
Cury et al. (2015). These criteria have been demonstrated to have high
intra-rater and inter-rater reproducibility (Cury et al., 2015).
In the analysis, IHI as deﬁned by partial IHI (score 1 of individual
criteria C0) or total IHI (score 2 of individual criteria C0) was chosen
as the primary outcome. Total IHI, IHI score (sum of individual criteria
C1 to C5) and IHI score ≥ 4 (optimal threshold for total IHI in Cury
et al., 2015) were taken as secondary outcomes.
IHI was assessed blind to patient/control status, clinical and volu-
metric data. IHI were evaluated on the total sample by an expert (CC),
who had previously evaluated about 1000 subjects for the presence of
IHI. In order to assess inter-rater reliability, 60MDD patients were eval-
uated by a second rater (RC) after three training sessions. Consistently
with the results reported in the paper of Cury et al. (2015), we found
a strong inter-rater reliability (Cohen's kappa =0.80).
2.5. Hippocampal volumetry
The segmentation of the hippocampus was performed using the
fully automatic SACHA software (Chupin et al., 2007; Chupin et al.,
2009; Colliot et al., 2008). This approach segments the hippocampus
based on competitive region-growing between hippocampus and
amygdala. It includes prior knowledge on the location of the hippocam-
pus and the amygdala derived from a probabilistic atlas and on the rel-
ative positions of this structure with respect to anatomical landmarks,
which are automatically identiﬁed. All resulting segmentations were
assessed for segmentation quality (from 0 for worst quality to 4 for per-
fect quality) by trained raters (R.C and M.C), blind to the study group
(patients versus controls) and sociodemographic and clinical data.
Only high quality segmentations (quality score ≥ 2) were included in
the analysis: three patients and four controls were excluded from the
volumetric analyses. Automated segmentationwas preferred tomanual
segmentation ﬁrst because manual assessment cannot be performed
blind to IHI, second because automated segmentation has been vali-
dated as compared to manual segmentation in previous studies (Dill
et al., 2015), and because it is faster, requires less speciﬁc anatomical ex-
pertise and does not suffer from high intra- and inter-rater variability.
SACHA was previously validated in depressed patients (Bergouignan
et al., 2009).
Total brain volume was determined with SPM5 to analyze hippo-
campal volume (mean, right and left) adjusted to total brain volume.
Because brain volume, age and gender are known to be associated
with hippocampal volume, non-matched analyses were adjusted on
brain volume, age and gender.
No statistically signiﬁcant difference for segmentation quality scores
was shown in patients with right (partial + total) IHI as compared to
patients without right (partial + total) IHI (m(sd) 2.4 (0.7) vs m(sd)
2.8(0.5), p = 0.24), and in patients with left (partial + total) IHI ascompared to patients without left (partial + total) IHI (m(sd) 2.6(0.5)
vs m(sd) 2.8 (0.4), p = 0.28).2.6. Assessment of response and remission after antidepressant treatment
TheHDRS scale (Hamilton, 1960)was rated in depressed patients by
trained clinicians at baseline, one month, three months and six months
after the beginning of antidepressant treatment. These raterswere blind
from MRI data. The percentage of remitters six months post-treatment
was deﬁned a-priori as the main outcome measure. A HDRS score of
seven or less at follow-up deﬁned remitters. Secondary outcomes
were the percentage of decrease of the HDRS score between baseline
and follow-up and the percentage of responders, response being de-
ﬁned by a decrease in the HDRS score of at least 50% from baseline to
follow-up.2.7. Statistical methods
First, bivariate analyseswere performed usingχ2 tests for categorical
variables and Wilcoxon tests for continuous variables. Linear or logistic
regressions were used to assess interaction effects between IHI and HV
on antidepressant efﬁcacy (HDRS improvement, response and
remission).
A Receiver Operating Characteristic curvewas built to determine the
optimal HV threshold associated with remission after six months of an-
tidepressant treatment in patients without left IHI. A sensitivity/speci-
ﬁcity analysis was performed on left hippocampal volumes.
All tests were two-tailed. Signiﬁcance level was deﬁned as p b 0.05.
All tests were performed with R 2.15.3. A power estimation was per-
formed with G*power 3.1.3. Results
3.1. Sample
The 60 MDD patients and the 60 matched controls had a mean (sd)
age of 45.7 (12.8) years for patients and 45.4 (12.8) years for controls
(p = 0.89) and 36 (60%) were women in each group (p = 1.0). The
mean (sd) hippocampal volumes did not signiﬁcantly differ between
MDDpatients (right: 2.55 cm3 (0.61), left: 2.51 cm3 (0.54)) and controls
(right: 2.53 cm3 (0.51), left: 2.58 cm3 (0.47)).3.2. Is the prevalence of IHI higher in MDD compared to controls?
The prevalence of right and left IHI (partial, total, IHI subcriteria
score) did not signiﬁcantly differ between MDD patients and controls
(Table 1). The IHI total score did not signiﬁcantly differ between MDD
patients and controls (patients: m(sd) = 3.5 (2.6), controls: m(sd) =
3.3 (2.6), t = 0.32, p = 0.74).3.3. Is IHI related to speciﬁc sociodemographic or clinical characteristics in
patients with MDD?
IHI (partial + total) was not signiﬁcantly associated with age, sex,
recurrent MDD, MDD duration, HDRS score at baseline and previous
lifetime duration of antidepressant treatment (Table 2).3.4. Is IHI related to hippocampal volume in patients with MDD?
HV did not differ between patients with or without IHI
(partial + total) (Table 2).
Table 1
IHI frequency in patients and controls.
Right hippocampus Left hippocampus
Patients Controls Test p Patients Controls Test p
Partial + total IHI n (%) 14 (23.3) 10 (16.7) X2 = 0.8 0.36 23 (38.3) 20 (33.3) X2 = 0.3 0.57
Total IHI n (%) 6 (10.0) 4 (6.7) X2 = 0.4 0.51 13 (21.7) 9 (15.0) X2 = 0.9 0.35
Partial IHI n (%) 8 (13.3) 6 (10.0) X2 = 0.3 0.56 10 (16.4) 11 (18.3) X2 = 0.1 0.81
C1 m(sd) 0.4 (0.5) 0.3 (0.4) t =−1.2 0.25 0.5 (0.5) 0.5 (0.5) t = 0.1 0.93
C2 m(sd) 0.5 (0.5) 0.5 (0.5) t =−0.1 0.92 0.6 (0.6) 0.5 (0.5) t =−1.0 0.34
C3 m(sd) 0.4 (0.4) 0.4 (0.4) t =−0.5 0.65 0.6 (0.5) 0.6 (0.5) t = 0.2 0.86
C4 m(sd) 0.0 (0.0) 0.0 (0.0) na na 0.0 (0.0) 0.0 (0.0) na na
C5 m(sd) 0.1 (0.5) 0.1 (0.5) t = 0.0 1 0.5 (0.8) 0.4 (0.8) t =−0.2 0.82
IHI score m(sd) 1.3 (1.3) 1.3 (1.3) t =−0.1 0.89 2.2 (1.7) 2.0 (1.7) t =−0.4 0.70
IHI score ≥ 4 n (%) 6 (10) 6 (10.0) t = 0.0 1 14 (23.3) 10 (16.7) t = 2.0 0.15
Legends: MDD: Major Depressive Disorder; Major Depressive Episode; IHI: Incomplete Hippocampal Inversion; C: criteria.
X2 = Chi square; t = Student t-test.
952 R. Colle et al. / NeuroImage: Clinical 12 (2016) 949–9553.5. Does hippocampal volume alone predict response/remission after
antidepressant treatment in MDD patients?
Right hippocampal volumes were associated neither with
sociodemographic characteristics (age: r = 0.05, p = 0.70; Sex: w =
470, p = 0.24) nor with clinical characteristics (recurrent MDD: w =
315, p = 0.67; MDD duration: r = 0.02, p = 0.90; HDRS score at base-
line: r = 0.07, p= 0.60; antidepressant naive: w= 358; p= 0.30; pre-
vious antidepressant treatment duration: r =−0.05; p = 0.74).
Left hippocampal volumes were associated neither with
sociodemographic characteristics (age: r = 0.01, p = 0.97; Sex: w =
462, p = 0.97) nor with clinical characteristics (recurrent MDD: w =
291, p = 0.37; MDD duration: r = 0.10, p = 0.46; HDRS score at base-
line: r = 0.08, p= 0.56; antidepressant naive: w= 310; p= 0.36; pre-
vious antidepressant treatment duration: r =−0.07; p = 0.64).
HV (right and left) were not signiﬁcantly associated with response
and remission rates after antidepressant treatment (Table 3).Table 2
IHI and sociodemographical characteristics, clinical characteristics and antidepressant efﬁcacy.






Hippocampal volume (m(sd)) cm3 2.442 (0.602) 2.568 (0.617) w
Age (m(sd)) 46.4 (12.5) 45.5 (13.0) w
Women (%) 64.3 58.7 X2
Recurrent MDD (%) 64.3 69.6 X2
MDD duration (m(sd)) years 11.6 (15.5) 7.7 (10.1) w
HDRS (m(sd)) 22.0 24.6 w
AD naïve (%) 7.1 28.3 X2
Anterior AD duration (m(sd)) years 4.1 (5.6) 2.1 (4.1) w
Non treated MDD duration (m(sd)) years 8.5 (12.7) 5.2 (8.9) w
Antidepressant
SSRI (%) 32.6 28.6 X2
SNRI (%) 58.7 58.7
TCA (%) 57.1 8.7
M1 n = 13 n = 37
% HDRS improvement (m(sd)) 35.4 (29.7) 49.2 (26.0) w
Response (%) 46.2 51.4 X2
Remission (%) 15.4 27.0 X2
M3 n = 9 n = 23
% HDRS improvement (m(sd)) 42.9 (32.3) 49.0 (32.5) w
Response (%) 33.3 56.5 X2
Remission (%) 33.3 26.1 X2
M6 n = 7 n = 17
% HDRS improvement (m(sd)) 46.6 (45.7) 47.7 (38.6) w
Response (%) 47.1 71.4 X2
Remission (%) 42.9 41.2 X2
Legends: IHI: Incomplete Hippocampal Inversion;MDD:Major Depressive Disorder; HDRS: Ham
hibitor; SNRI: Serotonin and Noradrenaline Reuptake Inhibitor; TCA: Imipraminics; M1: 1 mon
square; w: Wilcoxon test.3.6. Does IHI alone predict response/remission after antidepressant treat-
ment in MDD patients?
IHI (either left or right, partial + total IHI, Total IHI and IHI score ≥ 4)
was not associated with remission, response, or HDRS score improve-
ment, neither after one, three or six months post-treatment (Table 2).
3.7. Does taking into account IHI improve the value of hippocampal volume
in the prediction of response/remission after antidepressant treatment in
MDD patients?
Table 3 shows the association between HV and antidepressant efﬁ-
cacy in the whole sample, and in patients with or without IHI.
Signiﬁcant statistical interactions between left HV and left IHI were
found to predict antidepressant remission after three months (p =
0.04) and six months (p= 0.03) of antidepressant treatment, these in-
teractions remaining signiﬁcant after adjustment on brain volume, ageLeft IHI (partial + total)
t p Yes (n = 23) No (n = 37) Test p
= 264 0.40 2.577 (0.557) 2.494 (0.537) w = 319 0.72
= 317.5 0.94 45.3 (11.3) 46.1 (13.8) w = 457 0.64
= 0.1 0.71 56.5 62.2 X2 = 0.2 0.67
= 0.1 0.71 73.9 64.9 X2 = 0.5 0.46
= 290 0.66 11.7 (14.3) 6 0.7 (9.1) w = 327 0.17
= 412 0.12 24.0 (4.3) 24.0 (5.4) w = 403 0.74
= 2.7 0.11 13.0 29.7 X2 = 2.2 0.14
= 198.5 0.09 3.5 (6.1) 1.9 (3.1) w = 292.5 0.22
= 252 0.41 7.2 (11.9) 5.2 (9.6) w = 310.5 0.27
= 0.4 0.82 30.4 32.4 X2 = 2.3 0.32
52.2 62.2
17.4 5.4
n = 18 n = 32
= 306 0.15 44.8 (30.7) 46.1 (25.8) w = 287.5 1
= 0.1 0.74 61.1 43.8 X2 = 1.4 0.23
= 0.7 0.40 27.8 21.9 X2 = 0.2 0.63
n = 11 n = 21
= 113 0.71 39.7 (30.1) 51.3 (33.1) w = 141 0.32
= 1.4 0.24 36.4 57.1 X2 = 1.2 0.26
= 0.2 0.68 27.3 28.6 X2 = 0.0 0.94
n = 8 n = 16
= 58 0.95 40.2 (40.6) 51.0 (40.2) w = 76 0.49
= 1.19 0.28 56.2 50.0 X2 = 0.1 0.77
= 0.0 0.93 62.5 43.8 X2 = 0.1 0.77
ilton Depression Rating Scale; AD: antidepressant; SSRI: Selective Serotonin Reuptake In-
th post-treatment, M3: 3 months post-treatment; M6: 6 months post-treatment; X2: Chi
Table 3
Hippocampal volume as predictor of antidepressant efﬁcacy with or without taking into account IHI.
% HAMD-17 improvement p Responders Non Responders p Remitters Non Remitters p
Total sample (n= 60)
M1 (n = 46)
Right Hippocampus volume (m(sd)) cm3 r =−0.07 0.64 2.63 (0.66) 2.53 (0.66) 0.97 2.76 (0.57) 2.52 (0.60) 0.45
Left hippocampus volume (m(sd)) cm3 r = 0.01 0.95 2.56 (0.60) 2.56 (0.57) 0.80 2.68 (0.61) 2.52 (0.57) 0.52
M3 (n = 30)
Right Hippocampus volume (m(sd)) cm3 r = 0.08 0.67 2.70 (0.65) 2.50 (0.52) 0.35 2.86 (0.57) 2.49 (0.59) 0.14
Left hippocampus volume (m(sd)) cm3 r = 0.21 0.27 2.69 (0.71) 2.30 (0.40) 0.11 2.71 (0.73) 2.41 (0.54) 0.23
M6 (n = 24)
Right Hippocampus volume (m(sd)) cm3 r = 0.09 0.64 2.72 (0.58) 2.54 (0.69) 0.42 2.75 (0.60) 2.54 (0.66) 0.42
Left hippocampus volume (m(sd)) cm3 r = 0.19 0.37 2.61 (0.72) 2.37 (0.55) 0.34 2.41 (0.54) 2.39 (0.53) 0.34
Patients with left IHI (n= 23)
M1 (n = 15)
Left hippocampus volume (m(sd)) cm3 r = 0.03 0.91 2.55 (0.83) 2.73 (0.39) 0.52 2.55 (0.83) 2.59 (0.53) 0.99
M3 (n = 9)
Left hippocampus volume (m(sd)) cm3 r =−0.42 0.27 2.39 (0.96) 2.41 (0.34) 0.90 1.98 (0.62) 2.61 (0.58) 0.26
M6 (n = 7)
Left hippocampus volume (m(sd)) cm3 r =−0.57 0.20 1.98 (0.623) 2.65 (0.66) 0.40 1.98 (0.62) 2.64 (0.66) 0.40
Patients without left IHI (n= 37)
M1 (n = 29)
Left hippocampus volume (m(sd)) cm3 r = 0.02 0.94 2.60 (0.552) 2.51 (0.56) 0.91 2.77 (0.48) 2.50 (0.56) 0.38
M3 (n = 19)
Left hippocampus volume (m(sd)) cm3 r = 0.34 0.16 2.74 (0.635) 2.33 (0.38) 0.18 2.95 (0.57) 2.39 (0.49) 0.09
M6 (n = 15)
Left hippocampus volume (m(sd)) cm3 r= 0.63 0.01 2.86 (0.54) 2.18 (0.42) 0.03 2.97 (0.53) 2.26 (0.43) 0.02
Legends: IHI: Incomplete Hippocampal Inversion; M1: 1 month post-treatment; M3: 3 months post-treatment; M6: 6 months post-treatment.
953R. Colle et al. / NeuroImage: Clinical 12 (2016) 949–955and gender (p = 0.04 and p = 0.04 respectively) and MRI acquisition
sequences (p = 0.04 and p = 0.06 respectively). Accordingly, signiﬁ-
cant statistical interactions were found for response (p = 0.04, p =
0.07 after adjustment on brain volume, age and gender, and p = 0.03
after adjustment on MRI acquisition sequences) and HDRS improve-
ment (p = 0.02, p = 0.04 after adjustment on brain volume, age and
gender, and p = 0.004 after adjustment on MRI acquisition sequences)
after sixmonths of antidepressant treatment. Of note, no signiﬁcant sta-
tistical interactions between right HV and right IHI were found for the
prediction of antidepressant response/remission.
Thus, in patients without left IHI, HV at baseline did predict re-
sponse, remission and HDRS score decrease post-treatment and re-
maining signiﬁcant after adjustment on MRI acquisition sequences for
HDRS score decreased after six month of antidepressant treatment
(p = 0.01). On the contrary, in patients with left IHI, HV at baseline
did not predict remission, response or HDRS score decrease post-
treatment. Indeed, non-remitters and non-responders six months
post-treatment had signiﬁcantly smaller left hippocampus at baseline
than remitters and responders respectively. A trend was also shown
for three-month remission.
Since there aremore patients in the subgroup of patientswithout IHI
criteria, resulting in different powers that could explain the results, a
case-control design on matched patients (15 with left IHI and 15 with-
out left HI matched for age and sex) was secondary applied, conﬁrming
the statistical interaction of IHI andHV for HDRS score improvement six
months post-treatment (p = 0.046) and at a trend for remission after
three months (p = 0.06) and six months (p = 0.07) of treatment.
This case-control design conﬁrmed that, in patients without left IHI,
HV at baseline was smaller for non-responders as compared to re-
sponders after six months of antidepressant treatment (1.97
(0.34) cm3 vs 2.93(0.45) cm3, p = 0.02). There was a similar trend for
remission after six months of antidepressant treatment (2.15
(0.49) cm3 vs 2.94(0.52) cm3, p=0.06). Accordingly, therewas a signif-
icant correlation between HV at baseline and HDRS score decrease after
6 months of antidepressant treatment (r = 0.70, p = 0.04).
To predict six-month remission with left HV in patients without IHI,
a ROC analysis showed that the Area Under the Curve (AUC) was 0.86
(95%CI [0.66; 1.00]) (Fig. S1). In this sample, a left hippocampalvolume N 2.50 cm3 had a 86% sensitivity, a 75% speciﬁcity, a 75% positive
predictive value, and a 86% negative predictive value. A left hippocam-
pal volume b 2.87 cm3 had a 57% sensitivity, a 100% speciﬁcity, a 100%
positive predictive value and a 73% negative predictive value.
4. Discussion
To the best of our knowledge, this is the ﬁrst study of IHI inMDDpa-
tients. IHI does not appear to be signiﬁcantly more frequent in MDD pa-
tients than in controls, is not associatedwithMDD characteristics, is not
predictive of treatment response when considered alone but is a con-
founder that decreases the relevance of hippocampal volume to predict
remission after antidepressant treatment. Thus, taking into account IHI
could improve the relevance of HV to predict antidepressant response
or remission after antidepressant treatment.
Some clinical studies reported that HV could predict response or re-
mission after antidepressant treatment of a Major Depressive Episode
(MacQueen et al., 2008; Sheline et al., 2012). However, other studies
failed to replicate these results (Frodl et al., 2008; Hsieh et al., 2002;
Janssen et al., 2007; Vakili et al., 2000). Similarly to these previous neg-
ative reports, HV, when considered alone, did not signiﬁcantly predict
antidepressant response or remission in our sample, even if baseline
HVwere lower in patients with non-response/remission, but this differ-
ence was not statistically signiﬁcant. This discrepancy between studies
on the predictive value of HV could be due to the presence of IHI,
which was not taken into account in previous volumetric studies. In-
deed, in our study, while neither HV, nor IHI were predictivewhen con-
sidered alone, the interaction between HV and IHI predicted response
and remission. Furthermore, a previous meta-analysis (Fu et al., 2013)
reported that only right hippocampal volume and not left hippocampal
volume predict antidepressant response/remission.
Our results about the prevalence of IHI in controls are similar to
those of a recent study a community-based sample of over 2000 normal
and young subjects in general population (Cury et al., 2015) for right
and left IHI (total + partial right IHI frequency 16.7% vs 15.5% and
total + partial left IHI frequency 33.3% vs 29%). In our study, the fre-
quency of IHI was not signiﬁcantly higher in MDD patients than in con-
trols. This point does not argue for IHI as a neurodevelopmental risk
954 R. Colle et al. / NeuroImage: Clinical 12 (2016) 949–955marker for MDD. Nevertheless, this would need to be conﬁrmed in a
larger sample. Since the correlations between hippocampal volumes
and HRDS improvement seem to be negative in patients with left IHI
(although not signiﬁcant) and positive in patients without IHI, this
point should be further studied in greater sample sizes, in order to test
whether or not these associations can reach statistical signiﬁcance
with greater statistical power.
Our study has the following limitations.
The ﬁrst limitation is the statistical power of this study. While IHI
was not signiﬁcantly more frequent in MDD patients than in controls,
our sample was relatively small and could have a too low statistical
power to detect such a small effect. Indeed, the number of patients
with three and six-month prospective assessments was relatively
small, due to attrition. This is however similar to the attrition rate of
other naturalistic studies in MDD such as STAR*D (Trivedi et al., 2006).
Thus, there is a risk of false negative results (lack of power particularly
in the subgroup of patients with IHI). Nevertheless, to control for this
potential limitation, we performed a second analysis using a matched
case-control design (with and without left IHI), which conﬁrmed our
primary results. Moreover, we observed no statistical difference of HV
betweenMDDpatients and controls andwere unable to replicate the re-
sult of the recent paper of the ENIGMAMajor DepressiveDisorderwork-
ing group published by Schmaal et al., 2015. This is probably due to the
fact that the effect size described in the literature is too small to be de-
tected with the power of our study (Kempton et al., 2011; Schmaal
et al., 2015). The lack of power of our study may also explain that mul-
tiple adjustments may lead to statistical trends rather than statistically
signiﬁcant results. Of note, we used no corrections for multiple testing.
Consequently, in future replication studies, a larger sample size and cor-
rections for multiple comparisons would be required to conﬁrm our
preliminary exploratory results.
The second limitation of this study is that it relies only on automatic
segmentation. It has been previously shown that the accuracy of auto-
matic hippocampal segmentation is affected by the presence of IHI
(Kim et al., 2012). It is thus possible that the confounding effect of IHI
on HV could be due to a lower accuracy of the segmentation in IHI pa-
tients. Nevertheless, in our study, we performed systematic visual qual-
ity control of the segmentation results and only high quality
segmentations were included in the analysis (three patients and four
controls were excluded from the volumetric analyses). Furthermore,
we did not ﬁnd any statistically signiﬁcant difference between patients
with or without left IHI for segmentation quality scores (m(sd) 2.7(0.5)
vsm(sd) 2.8(0.4), p=0.20). However, addingmeasurements of aman-
ual segmentation in addition to the automated one would have
strengthened our results, and would be useful in future replication
studies.
5. Conclusion
In conclusion, IHI is a confounder that decreases the predictive value
of hippocampal volume to predict remission after antidepressant
treatment.
An independent and large cohort using both automatic and manual
segmentation is needed to replicate our results. Nevertheless, our re-
sults clearly demonstrate that IHI assessment is important when
conducting volumetric studies.We recommend to systematically assess
IHI in future research studies assessing hippocampal volume in MDD.
Whether this assessment should be implemented in clinical practice
has to be clariﬁed by further studies.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.nicl.2016.04.009.
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